Skip to main content
  • Saved

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk - American College of Cardiology

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk - American College of Cardiology

Source : https://www.acc.org/latest-in-cardiology/clinical-trials/2017/03/16/00/46/fourier

The FOURIER trial showed that evolocumab was superior to placebo at reducing adverse cardiovascular events. The goal of the trial was to evaluate the efficacy and safety of evolocumab, a PCSK9 inhibitor, among subjects with elevated cardiovascular risk on statin therapy.